Journal article

A generic high-dose rate Ir-192 brachytherapy source for evaluation of model-based dose calculations beyond the TG-43 formalism

Facundo Ballester, Asa Carlsson Tedgren, Domingo Granero, Annette Haworth, Firas Mourtada, Gabriel Paiva Fonseca, Kyveli Zourari, Panagiotis Papagiannis, Mark J Rivard, Frank-Andre Siebert, Ron S Sloboda, Ryan L Smith, Rowan M Thomson, Frank Verhaegen, Javier Vijande, Yunzhi Ma, Luc Beaulieu

MEDICAL PHYSICS | WILEY | Published : 2015


PURPOSE: In order to facilitate a smooth transition for brachytherapy dose calculations from the American Association of Physicists in Medicine (AAPM) Task Group No. 43 (TG-43) formalism to model-based dose calculation algorithms (MBDCAs), treatment planning systems (TPSs) using a MBDCA require a set of well-defined test case plans characterized by Monte Carlo (MC) methods. This also permits direct dose comparison to TG-43 reference data. Such test case plans should be made available for use in the software commissioning process performed by clinical end users. To this end, a hypothetical, generic high-dose rate (HDR) (192)Ir source and a virtual water phantom were designed, which can be imp..

View full abstract

University of Melbourne Researchers


Awarded by GeneralitatValenciana

Awarded by Spanish Government

Awarded by Canadian Cancer Society Research Institute (CCSRI)

Awarded by Swedish Cancer Foundation

Funding Acknowledgements

The authors acknowledge Sophie Wetherall and Rebecca Park from Varian, Yury Niatsetski and Bob van Veelen from Elekta, and Greg Failla and Todd Wareing from Transpire, Inc., for their support. Varian and Elekta provided the authors access to their latest versions of ACUROS and ACE software. F.B. and J.V. thank the support provided by GeneralitatValenciana under Project No. PROMETEOII/2013/010 and by the Spanish Government under Project No. FIS2013-42156. F.V., R.M.T., L.B., and Y.M. thank the support provided by the Canadian Cancer Society Research Institute (CCSRI) Grant No. 2011-700810. R.M.T. acknowledges support from NSERC, the CRC program, and Carleton University's Office of the VP (Research and International). A.C.T. acknowledges the Swedish Cancer Foundation, Grants Nos. CF 11 0495, CF 13 0470 and CF 14 0641.